[Prolipase in the treatment of dyspepsia in chronic liver diseases].
In 12 patients with chronic liver disease without detectable pancreatic insufficiency the authors tested in clinical trials the pancreatic enzyme preparation Prolipase (Cilag AG, Switzerland) in an attempt to influence the marked dyspeptic complaints of patients. They administered three times per day two capsules before meals for a period of three weeks. Half the patients evaluated the therapeutic effect as excellent, one quarter as very good, only one quarter did not observe a marked favourable effect on dyspepsia. Treatment was well tolerated and no undesirable side-effects were observed. Prolipase can thus be used in dyspepsias associated with chronic hepatic lesions.
Brodanová
M
M
I. Interní klinika 1. lékarské fakulty Univerzity Karlovy, Praha.
Kordac
V
V
D002908:Chronic Disease; D004415:Dyspepsia / Q000188:drug therapy* / Q000209:etiology; D057487:Enzyme Therapy; D004798:Enzymes; D006521:Hepatitis, Chronic / Q000150:complications; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications; D008107:Liver Diseases / Q000150:complications*; D010184:Pancreatic Extracts / Q000627:therapeutic use*
D004798:Enzymes; D010184:Pancreatic Extracts; C070436:Prolipase
Prolipase v lécení dyspepsie u chronických jaterních chorob.